Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Head and Neck Neoplasms 3 Esophageal Neoplasms 3 Prostatic Neoplasms 2 Phyllodes Tumor 2 Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Sarcoma 1 Postoperative Complications 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Mouth Neoplasms 1 Lymphatic Metastasis 1 High-Risk Cancer 1 Carcinoma, Lobular 1

Interventions

Gemcitabine 87 Cisplatin 66 Cystectomy 38 pembrolizumab 34 Docetaxel 25 Nivolumab 24 durvalumab 21 Paclitaxel 19 Magnetic Resonance Spectroscopy 18 Radiotherapy 17 Mitomycin 17 Carboplatin 16 atezolizumab 15 Doxorubicin 14 Cystoscopy 14 BCG Vaccine 13 Surveys and Questionnaires 12 Standard of Care 12 avelumab 11 Sunitinib 10 tremelimumab 9 Transurethral Resection of Bladder 9 Ipilimumab 9 Filgrastim 9 Blood Specimen Collection 9 Specimen Handling 8 Neoadjuvant Therapy 8 Methotrexate 8 Methods 8 Early Intervention, Educational 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urinary Bladder Neoplasms × Radiotherapy, Adjuvant × Clear all

NCT05445648 2022-12-28

CBPTMI

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡